Masseter Botox for TMJ: Benefits, Limits and Risks

Masseter Botox weakens a major chewing muscle temporarily. Botox is a brand of botulinum toxin type A; other products use different formulations and dosing units. The treatment may help some people whose temporomandibular disorder (TMD) pain comes mainly from overactive, painful chewing muscles. It does not repair the jaw joint, reposition a displaced disc or address every cause of clenching and grinding.

Treatment for TMD is off-label in the United States. Botox is FDA-approved for conditions including chronic migraine and spasticity, but not TMD. The National Institute of Dental and Craniofacial Research (NIDCR) says study results are mixed and it remains unclear whether botulinum toxin relieves TMD symptoms (NIDCR).

When is it a closer match?

“TMJ” is often used as a catch-all, but the TMJ is the joint. TMD includes disorders involving the joints, chewing muscles and related structures. Masseter injections are a closer biological match when an examination reproduces the person’s familiar pain in that muscle and supports a diagnosis of myofascial TMD—pain arising from the chewing muscles.

They are a weaker match for:

• painless clicking or popping, which generally does not need treatment
• pain arising mainly inside the joint, such as from arthritis or a disc disorder
• a tooth, ear, sinus or nerve condition that feels like jaw pain
• jaw locking that has not been evaluated
• bruxism when the main goal is protecting teeth from wear rather than reducing muscle pain

Botulinum toxin reduces the force produced by an injected muscle. That is not the same as stopping the underlying clenching or grinding activity. A 2024 review of 14 randomized trials found no significant advantage over placebo for pain, mouth opening, bruxism events or maximum bite force (PLOS One).

An assessment should therefore identify whether the familiar pain comes from the masseter, another chewing muscle, the joint or a different structure—not infer the source from “jaw tension” alone.

How good is the evidence?

The evidence is genuinely conflicting.

The 2024 PLOS One meta-analysis found botulinum toxin no better than placebo for pain at one, three or six months. Another 2024 systematic review reached a more favorable conclusion for myofascial TMD pain, but only six of its 20 randomized trials could be combined in the meta-analysis; 13 trials raised some risk-of-bias concerns. It reported pain relief but no improvement in maximum mouth opening, and its authors suggested considering low doses only when conservative treatment had not provided enough relief (Medicine).

Small trials can also look promising. In one double-blind trial of severe, muscle-led pain that had not improved by at least 30% after three conservative treatments, 32 people were randomized and 28 completed follow-up. Botulinum toxin produced better pain outcomes than saline at one and six months. The small, narrowly selected sample makes the finding more relevant to refractory myofascial pain than to everyone with a “TMJ problem” (Scientific Reports).

A 2023 BMJ guideline for chronic TMD pain lasting at least three months made a conditional recommendation against botulinum toxin. It strongly favored options including supervised jaw exercise and stretching, therapist-assisted mobilization, postural exercise and cognitive behavioral therapy (BMJ). “Conditional against” does not mean nobody can benefit. It means most informed patients would probably decline because the expected benefit is uncertain relative to the burdens and harms.

What treatment involves

The injector places botulinum toxin type A into selected points in the masseter. Depending on the pain pattern, another chewing muscle such as the temporalis may also be considered. Treating the masseters alone should not be assumed to cover pain arising elsewhere.

There is no FDA-approved TMD protocol or standard TMD dose. Trials vary substantially in products, muscles and amounts. Botox units cannot be compared with or converted directly into the units of another botulinum toxin product, according to the US prescribing information. See how product, muscle selection and laterality affect the quoted dose.

The result is not immediate. Guys and St Thomas’ NHS Foundation Trust tells its TMD patients that the toxin may take up to 10 days to start working and up to three weeks for its full effect; its service describes effects lasting about six months on average, with individual variation (Guys and St Thomas’ NHS Foundation Trust).

Before considering repeat injections, compare the same outcomes recorded at baseline:

• average and worst pain
• ability to chew an ordinary meal
• comfortable mouth opening
• headache days, if relevant
• use of pain medicine
• unwanted weakness or changes in facial movement

A documented change in pain and function is more informative than a vague sense that the jaw “felt looser.”

Risks to discuss

Local effects can include injection-site pain, bruising, chewing fatigue or weakness, facial asymmetry and an altered smile. Weakening and shrinking the masseter may also change lower-face contour. Read more about why masseter injections can affect a smile.

Repeated treatment also raises an unresolved bone question. In a retrospective study of 77 women, two rounds of injections into the masseter and temporalis over six months were associated with radiographic changes in mandibular cortical thickness or density; some findings were more pronounced in postmenopausal participants. The study cannot show that the injections caused clinically important bone damage, and human evidence remains insufficient, but the uncertainty is worth discussing before long-term repeat treatment (Scientific Reports).

The official Botox label carries a boxed warning that toxin effects can spread beyond the injection area, with symptoms reported hours to weeks later. Seek immediate medical help for new trouble swallowing, speaking or breathing. Other possible symptoms include generalized weakness, double vision and drooping eyelids. The label also lists infection at the intended injection site and hypersensitivity to a botulinum toxin product as contraindications. Neuromuscular disorders and medicines that interfere with neuromuscular transmission can increase the effects, and the label notes potential fetal harm based on animal data (DailyMed). The prescriber should review pregnancy, medical conditions, medicines, previous toxin treatment and any swallowing or breathing problems.

Questions to ask the injector

1. What is my specific diagnosis, and what finding indicates that the masseter is a pain source?
2. Which product, muscles and sides will you inject, and why?
3. What conservative treatments should I try first or continue? NIDCR advises starting with simpler approaches such as reducing clenching and gum chewing, using appropriate heat or cold, and considering gentle exercise or physical therapy.
4. What measurable result will count as success, and when will we reassess it?
5. What is the plan if chewing weakness or a smile change occurs?
6. How will you decide whether another treatment is justified rather than repeating it automatically?
7. What training and experience do you have in diagnosing TMD, not only performing cosmetic injections?

A night guard may protect teeth but is not guaranteed to relieve TMD pain; design and monitoring matter. Compare the uses and risks of different TMJ mouthguards. Physical therapy, habit modification and behavioral pain strategies address different parts of the problem and may be used alone or together.

Masseter Botox is best viewed as a selective, temporary option—not a routine fix for every painful or noisy jaw. Prompt clinical assessment is more appropriate than injections or additional home treatment when the jaw locks, symptoms follow trauma, or pain occurs with fever, marked swelling, drainage, or difficulty eating or drinking.